<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
      <journal-id journal-id-type="pmc">ploscomp</journal-id>
      <journal-title-group>
        <journal-title>PLoS Computational Biology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1553-734X</issn>
      <issn pub-type="epub">1553-7358</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">PCOMPBIOL-D-12-01532</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pcbi.1002971</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Mathematics</subject>
          <subj-group>
            <subject>Applied mathematics</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Infectious diseases</subject>
            <subj-group>
              <subject>Viral diseases</subject>
              <subj-group>
                <subject>HIV</subject>
                <subj-group>
                  <subject>Retrovirology and HIV immunopathogenesis</subject>
                </subj-group>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Infectious disease modeling</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Infectious Diseases</subject>
          <subject>Mathematics</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Explaining the Determinants of First Phase HIV Decay Dynamics through the Effects of Stage-dependent Drug Action</article-title>
        <alt-title alt-title-type="running-head">Determinants of First Phase HIV Decay Dynamics</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Gilmore</surname>
            <given-names>James B.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Kelleher</surname>
            <given-names>Anthony D.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Cooper</surname>
            <given-names>David A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Murray</surname>
            <given-names>John M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <addr-line>School of Mathematics and Statistics, University of New South Wales, Sydney, New South Wales, Australia</addr-line>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <addr-line>The Climate Change Research Centre, University of New South Wales, Sydney, New South Wales, Australia</addr-line>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <addr-line>The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia</addr-line>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <addr-line>Centre for Applied Medical Research, St Vincent's Hospital, Darlinghurst, New South Wales, Australia</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Fraser</surname>
            <given-names>Christophe</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">
        <addr-line>Imperial College London, United Kingdom</addr-line>
      </aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">j.murray@unsw.edu.au</email></corresp>
        <fn fn-type="conflict">
          <p>The authors have declared that no competing interests exist.</p>
        </fn>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: JBG ADK DAC JMM. Performed the experiments: JBG JMM. Analyzed the data: JBG JMM. Contributed reagents/materials/analysis tools: JBG JMM. Wrote the paper: JBG ADK DAC JMM.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <month>3</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>28</day>
        <month>3</month>
        <year>2013</year>
      </pub-date>
      <volume>9</volume>
      <issue>3</issue>
      <elocation-id>e1002971</elocation-id>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>9</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>1</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-year>2013</copyright-year>
        <copyright-holder>Gilmore et al</copyright-holder>
        <license xlink:type="simple">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>A recent investigation of the effect of different antiretroviral drug classes on first phase dynamics of HIV RNA plasma virus levels has indicated that drugs acting at stages closer to viral production, such as the integrase inhibitor raltegravir, can produce a steeper first phase decay slope that may not be due to drug efficacy. Moreover it was found that for most drug classes the first phase transitions from a faster (phase IA) to a slightly slower decay region (phase IB) before the start of the usual second phase. Neither of these effects has been explained to date. We use a mathematical model that incorporates the different stages of the HIV viral life cycle in CD4+ T cells: viral entry, reverse transcription, integration, and viral production, to investigate the intracellular HIV mechanisms responsible for these complex plasma virus decay dynamics. We find differences in the phase IA slope across drug classes arise from a higher death rate of cells when they enter the productively infected stage post-integration, with a half-life of approximately 8 hours in this stage, whereas cells in earlier stages of the infection cycle have half-lives similar to uninfected cells. This implies any immune clearance is predominantly limited to the productive infection stage. We also show that the slowing of phase IA to phase IB at day 2 to 4 of monotherapy, depending on drug class, is a result of new rounds of infection. The level at which this slowing occurs is a better indicator of drug efficacy than the slope of the initial decay.</p>
      </abstract>
      <abstract abstract-type="summary">
        <title>Author Summary</title>
        <p>The infection of a cell by HIV proceeds through a series of stages and each stage can now be inhibited by an available antiretroviral drug class. It is known that different drug classes can result in different decay curves of plasma viral levels that are not well explained by current mathematical models of HIV dynamics. Here we develop a mathematical model that incorporates these stages of infection and show how it successfully reproduces plasma decay curves for the five classes of currently available antiretroviral drugs. Our modeling indicates that the efficacy of antiretroviral drugs is not solely described by the rate of decay of plasma viral levels as currently thought. Drugs such as the integrase inhibitor raltegravir will result in a faster initial decline of plasma viral levels compared to a drug that acts further from viral integration and production such as the CCR5 inhibitor maraviroc, even though they may have the same efficacy. Moreover, we find that infected cells only die at rates above the background level when they are in the productive phase, indicating that immune clearance is mostly absent from the early stages of HIV cellular infection. This is of particular concern given that most infected cells are in these early stages of infection.</p>
      </abstract>
      <funding-group>
        <funding-statement>The Kirby Institute is funded by the Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales. Its work is overseen by the Ministerial Advisory Committee on AIDS, Sexual Health and Hepatitis. This research was supported through a National Health and Medical Research Council (NHMRC) Practitioner Fellowship for ADK, and NHMRC Program Grant number 510448. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
      </funding-group>
      <counts>
        <page-count count="12"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Mathematical modeling of HIV infection has led to major advances in understanding HIV replication <italic>in vivo</italic> <xref ref-type="bibr" rid="pcbi.1002971-Ho1">[1]</xref>–<xref ref-type="bibr" rid="pcbi.1002971-Herz1">[4]</xref>. However, important questions still remain, and here we address how the underlying viral life cycle of HIV within CD4+ T cells can influence the first phase decay kinetics of HIV RNA plasma virus levels (pVLs) after the commencement of antiretroviral therapy (ART). We are motivated by results from trials with the integrase inhibitor (INI) raltegravir <xref ref-type="bibr" rid="pcbi.1002971-Murray1">[5]</xref> which produces a more extensive first phase decay than antiretroviral drugs from other classes. More recent investigations with drugs from a number of classes indicate that first phase decay rates can differ between drug classes and may not be constant over the entirety of the first phase <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>. The impact of the stage at which inhibition occurs within the viral life cycle on first phase decay is currently poorly understood.</p>
      <p>Early mathematical models estimated the underlying parameters of viral clearance and cell lifetimes from pVL dynamics <xref ref-type="bibr" rid="pcbi.1002971-Perelson1">[3]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Perelson2">[7]</xref>–<xref ref-type="bibr" rid="pcbi.1002971-Lloyd1">[10]</xref>. Some models incorporate time delays, and this has been shown to be particularly important in the modeling of HIV dynamics. Delays, which describe the amount of time required for HIV infection within a CD4+ T cell to progress from the stage inhibited by ART until viral production, are observed through an initial shoulder in pVL decay dynamics under ART <xref ref-type="bibr" rid="pcbi.1002971-Mittler1">[11]</xref>. Dixit <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1002971-Dixit1">[12]</xref> showed that by incorporating delays, HIV dynamics were more accurately modeled, especially when drug efficacy is less than 100%, as is the case <italic>in vivo</italic> <xref ref-type="bibr" rid="pcbi.1002971-Nelson1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Nelson2">[14]</xref>. The first phase decay rate has also been shown to be weakly dependent on the delay <xref ref-type="bibr" rid="pcbi.1002971-Nelson3">[15]</xref>. More complex time delay models have been introduced by Dixit and Perelson <xref ref-type="bibr" rid="pcbi.1002971-Dixit2">[16]</xref>, who examined pharmacokinetics in a model with two delays, and Ouifki and Witten <xref ref-type="bibr" rid="pcbi.1002971-Ouifki1">[17]</xref> who studied the stability of a three stage delay model.</p>
      <p>The stage of the viral life cycle at which a drug acts has been incorporated into HIV mathematical models <xref ref-type="bibr" rid="pcbi.1002971-Sedaghat1">[18]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-vonKleist1">[19]</xref>, and stage-dependent inhibition has also been demonstrated <italic>in vitro</italic>. Sedaghat <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1002971-Sedaghat1">[18]</xref> showed viral life cycle properties could impact pVL decline. In <xref ref-type="bibr" rid="pcbi.1002971-Donahue1">[20]</xref>, Donahue <italic>et al.</italic> verified that drugs from separate antiretroviral classes will result in different times until virion production, where these differences depended on the stage of the HIV infection cycle being inhibited.</p>
      <p>Recently, our group analyzed first phase dynamics during monotherapy with eight antiretroviral drugs <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>. Data were examined from early dose-ranging and viral dynamics studies of monotherapy with five drug classes: the INI raltegravir <xref ref-type="bibr" rid="pcbi.1002971-Murray1">[5]</xref>, the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine <xref ref-type="bibr" rid="pcbi.1002971-Goebel1">[21]</xref>, the nucleoside/nucleotide RTIs (NRTIs) abacavir and tenofovir <xref ref-type="bibr" rid="pcbi.1002971-Goicoechea1">[22]</xref>, the entry inhibitors (EIs) enfuvirtide <xref ref-type="bibr" rid="pcbi.1002971-Kilby1">[23]</xref> and maraviroc <xref ref-type="bibr" rid="pcbi.1002971-Fatkenheuer1">[24]</xref>, and the protease inhibitors (PIs) ritonavir <xref ref-type="bibr" rid="pcbi.1002971-Perelson1">[3]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Markowitz1">[25]</xref> and nelfinavir <xref ref-type="bibr" rid="pcbi.1002971-Moyle1">[26]</xref>. The time delay to initial pVL decay, when corrected for the pharmacokinetic delay, was found to increase as the inhibited replication stage is further from second generation viral export. These time delays were found to be about twice those observed for <italic>in vitro</italic> cell lines <xref ref-type="bibr" rid="pcbi.1002971-Kim1">[27]</xref>, indicating the process of viral replication occurs over a longer time period <italic>in vivo</italic> <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>. There was also evidence that the slope of the first phase becomes steeper for drugs with shorter time delays such as for the INI raltegravir. Moreover pVL decay was not constant over the course of what would be expected to be the first phase. The first phase of viral decay under monotherapy can be divided into two separate phases, IA and IB. Phase IA is the initial component of the first phase decay and lasts for 2–4 days. Phase IB follows and lasts until about day 10 with the phase IB decay being slower than the phase IA decay. Here we explore the biological determinants of these two phases in the context of stage-dependent modeling of drug inhibition.</p>
      <p>We model the HIV life cycle in CD4+ T cells by incorporating the time required for HIV to progress between the major stages of the viral life cycle. We consider each of the stages in the cycle that can be impacted by ART as separate, discrete but interrelated entities. We describe how the HIV life cycle in CD4+ T cells influences viral decay dynamics after the commencement of ART and determine the conditions under which the phase IA decay kinetics depends on the stage of the HIV life cycle being inhibited. We find that different slopes of the first phase decay are to be expected for antiretroviral agents from separate classes, and this does not necessarily reflect variations in drug efficacy. Moreover we find that this detailed analysis, when linked to observations <italic>in vivo</italic> <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>, indicates that the infected cell death rate only increases substantially above that for an uninfected cell at late stages of the infection cycle, belying any significant immune-mediated lysis during the pre-integration stages of infection.</p>
    </sec>
    <sec id="s2" sec-type="materials|methods">
      <title>Materials and Methods</title>
      <sec id="s2a">
        <title>Mathematical model</title>
        <p>We mathematically model the major steps of the HIV life cycle as interlinked processes with explicit time delays. To accomplish this, the viral life cycle is split into four major stages: viral entry, RT, IN and virion production as shown in <xref ref-type="fig" rid="pcbi-1002971-g001">Figure 1</xref>. Our model focuses on the initial time delay and the period normally described as encompassing first phase viral decay after the commencement of monotherapy and therefore describes the viral life cycle in CD4+ T cells that are destined for productive infection. Latently infected CD4+ T cells and long-lived infected cells are not included in the model, as they are thought to contribute to the classic second phase that commences approximately 10 days after administration of ART <xref ref-type="bibr" rid="pcbi.1002971-Perelson2">[7]</xref>.</p>
        <fig id="pcbi-1002971-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002971.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Model for HIV infection in CD4+ T cells.</title>
            <p>Production and loss includes CD4+ T cell production, CD4+ T cell death of infected and uninfected cells, and viral clearance. The major HIV infection stages in the model are: entry, reverse transcription, integration, and viral production. The model describes five types of CD4+ T cells: uninfected cells <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e001" xlink:type="simple"/></inline-formula>, cells where HIV has passed entry <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e002" xlink:type="simple"/></inline-formula>, cells where HIV has passed RT <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e003" xlink:type="simple"/></inline-formula>, cells where HIV has passed IN <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e004" xlink:type="simple"/></inline-formula>, and productively infected CD4+ T cells <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e005" xlink:type="simple"/></inline-formula>. Virus comprises infectious virus <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e006" xlink:type="simple"/></inline-formula>, and non-infectious virus <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e007" xlink:type="simple"/></inline-formula> (when PIs are administered).</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002971.g001" position="float" xlink:type="simple"/>
        </fig>
        <p>When constructing the life cycle stages, we are guided by the current classes of antiretroviral drugs that inhibit infectious virion production (PI), entry (EI), reverse transcription (NRTI and NNRTI), and integration (INI), and for which delay estimates have been derived <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>. Although data are available for two different mechanisms of RT inhibition, we describe RT inhibition in a single stage to retain model simplicity and clarity. This means the model assumes RT occurs at the average of the measurements in Murray <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref> derived from analysis of decay kinetics following monotherapy with two NRTIs (abacavir and tenofovir) and one NNRTI (rilpivirine), which determined a 33 hour time period over which reverse transcription occurs. Consequently the modeled stage after this average RT time point but before integration includes cells that have not completed RT. These simplifications result in a four stage model that retains mathematical tractability, while also allowing an in-depth examination of the viral dynamics that result from stage-dependent inhibition.</p>
        <p>The mathematical model is described by a system of seven first order differential equations, four of which are delay differential equations,<disp-formula id="pcbi.1002971.e008"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002971.e008" xlink:type="simple"/><label>(1)</label></disp-formula><disp-formula id="pcbi.1002971.e009"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002971.e009" xlink:type="simple"/><label>(2)</label></disp-formula><disp-formula id="pcbi.1002971.e010"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002971.e010" xlink:type="simple"/><label>(3)</label></disp-formula><disp-formula id="pcbi.1002971.e011"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002971.e011" xlink:type="simple"/><label>(4)</label></disp-formula><disp-formula id="pcbi.1002971.e012"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002971.e012" xlink:type="simple"/><label>(5)</label></disp-formula><disp-formula id="pcbi.1002971.e013"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002971.e013" xlink:type="simple"/><label>(6)</label></disp-formula><disp-formula id="pcbi.1002971.e014"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002971.e014" xlink:type="simple"/><label>(7)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e015" xlink:type="simple"/></inline-formula> is the number of uninfected CD4+ T cells in the body at time <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e016" xlink:type="simple"/></inline-formula> in days, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e017" xlink:type="simple"/></inline-formula> is the number of CD4+ T cells that have been infected by HIV that have passed the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e018" xlink:type="simple"/></inline-formula> stage in the life cycle but have not reached the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e019" xlink:type="simple"/></inline-formula> inhibitory stage. For example, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e020" xlink:type="simple"/></inline-formula> is the number of CD4+ T cells where HIV has passed the inhibitory effects of a RTI but where HIV DNA has not yet been integrated into the cell's genome. The mathematical model is represented schematically in <xref ref-type="fig" rid="pcbi-1002971-g001">Figure 1</xref>.</p>
        <p>Virions can only be produced when a CD4+ T cell becomes productively infected denoted by the stage <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e021" xlink:type="simple"/></inline-formula>. Virus is divided into two components describing infectious <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e022" xlink:type="simple"/></inline-formula> and non-infectious <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e023" xlink:type="simple"/></inline-formula> virus under the effects of a PI <xref ref-type="bibr" rid="pcbi.1002971-Perelson1">[3]</xref>. Although not all virions will be infectious even in the absence of a PI, we effectively incorporate this component into a lower infectivity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e024" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e025" xlink:type="simple"/></inline-formula> is the rate at which CD4+ T cells are infected, so that the non-infectious component under a PI is in addition to this background level. This is a simplification used by most authors modeling HIV dynamics, see for example <xref ref-type="bibr" rid="pcbi.1002971-Perelson2">[7]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Nelson3">[15]</xref>. The factor of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e026" xlink:type="simple"/></inline-formula> incorporates CD4+ T cell death during the time delay. When the CD4+ T cells are producing virions (as in <xref ref-type="disp-formula" rid="pcbi.1002971.e012">Eq. 5</xref>), we allow a different death rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e027" xlink:type="simple"/></inline-formula>, due to the immune response and/or cytopathic effects, compared to the death rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e028" xlink:type="simple"/></inline-formula> for the non-productive compartments. For perfectly efficacious drugs, this model can be solved exactly (see below).</p>
        <p>Although our focus is monotherapy, the model does admit stable viral loads prior to therapy and also shows rapid increases in viral load when therapy is interrupted or in primary infection scenarios.We note the sum of all CD4+ T cells will only be constant prior to therapy. The relative CD4+ T cell proportions change after therapy commences with all infected stages decreasing and uninfected CD4+ T cells increasing. Viral levels are also constant prior to therapy and decrease thereafter.</p>
        <p>Models that omit time delays allow some CD4+ T cells to progress from initial infection to viral production almost instantaneously. This is at odds with the time required for each of the biological mechanisms within the viral life cycle. To remedy this short-coming, each of the stages in our model incorporates its own time delay (see <xref ref-type="disp-formula" rid="pcbi.1002971.e008">Eqs. 1</xref>–<xref ref-type="disp-formula" rid="pcbi.1002971.e012">5</xref>). We have also linked the stages by the progression rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e029" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e030" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e031" xlink:type="simple"/></inline-formula>, resulting in two parameters controlling the progression of infection at each stage of the viral life cycle. Having two parameters describing each stage allows us to essentially describe the mean and variance for the time taken between life cycle stages.</p>
        <p>The parameters we use in the model are described in <xref ref-type="table" rid="pcbi-1002971-t001">Table 1</xref>. We have chosen the parameters to broadly agree with the values used in the literature for similar models, see for example <xref ref-type="bibr" rid="pcbi.1002971-Perelson1">[3]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Dixit1">[12]</xref>. We perform a sensitivity analysis on the model parameters to ensure our phase IA results are robust with regards to different parameter choices. As discussed later, phase IB is sensitive to most model parameters. The new parameters that we introduce to describe the life cycle are optimized to give good agreement with the monotherapy data we discuss later. Note that for the clearance rate, we take <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e032" xlink:type="simple"/></inline-formula> to agree with measurements derived from observations made during large volume plasma apheresis <xref ref-type="bibr" rid="pcbi.1002971-Ramratnam1">[9]</xref>, although similar results are obtained with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e033" xlink:type="simple"/></inline-formula> as estimated in Murray <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>.</p>
        <table-wrap id="pcbi-1002971-t001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002971.t001</object-id>
          <label>Table 1</label>
          <caption>
            <title>Summary of model parameters.</title>
          </caption>
          <alternatives>
            <graphic id="pcbi-1002971-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002971.t001" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Parameter</td>
                  <td align="left" rowspan="1" colspan="1">Value</td>
                  <td align="left" rowspan="1" colspan="1">Units</td>
                  <td align="left" rowspan="1" colspan="1">Description</td>
                  <td align="left" rowspan="1" colspan="1">Source/Notes</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e034" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e035" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e036" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">CD4+ T cell formation rate</td>
                  <td align="left" rowspan="1" colspan="1">Ref. <xref ref-type="bibr" rid="pcbi.1002971-Wei1">[2]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Sedaghat1">[18]</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e037" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e038" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e039" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">rate of entry</td>
                  <td align="left" rowspan="1" colspan="1">Ref. <xref ref-type="bibr" rid="pcbi.1002971-Dixit2">[16]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-vonKleist1">[19]</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e040" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">4.0</td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e041" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">progression rate of RT</td>
                  <td align="left" rowspan="1" colspan="1">This work</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e042" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">1.4</td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e043" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">progression rate of IN</td>
                  <td align="left" rowspan="1" colspan="1">This work</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e044" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">5.0</td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e045" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">progression rate to viral budding</td>
                  <td align="left" rowspan="1" colspan="1">This work</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e046" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e047" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">day</td>
                  <td align="left" rowspan="1" colspan="1">entry time delay</td>
                  <td align="left" rowspan="1" colspan="1">Ref. <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e048" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e049" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">day</td>
                  <td align="left" rowspan="1" colspan="1">RT time delay</td>
                  <td align="left" rowspan="1" colspan="1">Ref. <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e050" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e051" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">day</td>
                  <td align="left" rowspan="1" colspan="1">IN time delay</td>
                  <td align="left" rowspan="1" colspan="1">Ref. <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e052" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e053" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">day</td>
                  <td align="left" rowspan="1" colspan="1">production time delay</td>
                  <td align="left" rowspan="1" colspan="1">Ref. <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e054" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">0.05</td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e055" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">CD4+ T cell death rate</td>
                  <td align="left" rowspan="1" colspan="1">This work, Ref. <xref ref-type="bibr" rid="pcbi.1002971-Nelson1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Dixit2">[16]</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e056" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">2.5</td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e057" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">productive CD4+ T cell death rate</td>
                  <td align="left" rowspan="1" colspan="1">This work</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e058" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">2000</td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e059" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">virion production rate</td>
                  <td align="left" rowspan="1" colspan="1">Ref. <xref ref-type="bibr" rid="pcbi.1002971-Dixit2">[16]</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e060" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e061" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e062" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">viral clearance rate</td>
                  <td align="left" rowspan="1" colspan="1">Ref. <xref ref-type="bibr" rid="pcbi.1002971-Ramratnam1">[9]</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e063" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">0.90–1.00</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">EI efficacy</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e064" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">0.90–1.00</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">RTI efficacy</td>
                  <td align="left" rowspan="1" colspan="1">Monotherapy 0.90</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e065" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">0.90–1.00</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">INI efficacy</td>
                  <td align="left" rowspan="1" colspan="1">Exact solution 1.00</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e066" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">0.90–1.00</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">PI efficacy</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt101">
              <label/>
              <p>Parameters in the model were optimally chosen to match the monotherapy characteristics from Murray <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e067" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e068" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e069" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e070" xlink:type="simple"/></inline-formula> were chosen to be consistent with previous literature values.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>In the presence of ART, four steps in the viral life cycle can potentially be inhibited. To incorporate this effect for RTIs and INIs, we have included <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e071" xlink:type="simple"/></inline-formula> on the completion term for RT and IN in <xref ref-type="disp-formula" rid="pcbi.1002971.e010">Eqs. 3</xref> and <xref ref-type="disp-formula" rid="pcbi.1002971.e011">4</xref>, where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e072" xlink:type="simple"/></inline-formula> is the efficacy of the drug class in question. We assume abortive infection occurs for those T cells where the viral life cycle does not progress past the inhibition point of the drug class, see for example <xref ref-type="bibr" rid="pcbi.1002971-Doitsh1">[28]</xref>. Alternatively, these cells can be returned to the uninfected CD4+ T cell pool and simulations under this assumption produced virtually identical results to those described here. For EIs, we assume the rate of entry/infectivity, determined by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e073" xlink:type="simple"/></inline-formula>, is simply reduced by a factor <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e074" xlink:type="simple"/></inline-formula> from the outset in <xref ref-type="disp-formula" rid="pcbi.1002971.e008">Eqs. 1</xref> and <xref ref-type="disp-formula" rid="pcbi.1002971.e009">2</xref>. The use of a PI inhibits maturation of virions and results in non-infectious virus, as modeled in <xref ref-type="disp-formula" rid="pcbi.1002971.e013">Eqs. 6</xref> and <xref ref-type="disp-formula" rid="pcbi.1002971.e014">7</xref>. Note that the time delays in the model do not explicitly depend on drug efficacy. We assume no pharmacokinetic delay in the simulations of each drug class so that time zero is when each drug commences inhibition of its stage in the HIV life cycle. The pharmacokinetic delay can be incorporated by an additional delay, see <xref ref-type="bibr" rid="pcbi.1002971-Dixit2">[16]</xref> for example, however this has already been estimated and subtracted in the analysis presented in <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>.</p>
      </sec>
      <sec id="s2b">
        <title>Analytical solution with perfect efficacy</title>
        <p>When the efficacy of each monotherapy drug is perfect we can solve the system of equations analytically. For the case of INI monotherapy with perfect efficacy <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e075" xlink:type="simple"/></inline-formula>, the solution is <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e076" xlink:type="simple"/></inline-formula> for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e077" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e078" xlink:type="simple"/></inline-formula> is the pVL at <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e079" xlink:type="simple"/></inline-formula> before ART and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e080" xlink:type="simple"/></inline-formula> is the delay between HIV DNA integration and viral production, and for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e081" xlink:type="simple"/></inline-formula> we have<disp-formula id="pcbi.1002971.e082"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002971.e082" xlink:type="simple"/><label>(8)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e083" xlink:type="simple"/></inline-formula>. By examining the exponentials in <xref ref-type="disp-formula" rid="pcbi.1002971.e082">Eq. 8</xref>, the rate of viral decay for an INI will be determined by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e084" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e085" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e086" xlink:type="simple"/></inline-formula>. For RTI monotherapy with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e087" xlink:type="simple"/></inline-formula> the solution is <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e088" xlink:type="simple"/></inline-formula> for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e089" xlink:type="simple"/></inline-formula>, and for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e090" xlink:type="simple"/></inline-formula> we have<disp-formula id="pcbi.1002971.e091"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002971.e091" xlink:type="simple"/><label>(9)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e092" xlink:type="simple"/></inline-formula>. By examining the exponentials in <xref ref-type="disp-formula" rid="pcbi.1002971.e091">Eq. 9</xref>, the viral decay for an RTI will be determined by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e093" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e094" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e095" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e096" xlink:type="simple"/></inline-formula>. Compared to the INI, the presence of the rate of integration <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e097" xlink:type="simple"/></inline-formula>, means the RTI viral decay can be different (and less) than the INI. The expressions for the two remaining inhibition classes, EIs and PIs, have five and six terms incorporating all previous rates and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e098" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e099" xlink:type="simple"/></inline-formula> exponentiated respectively. These terms are analogous to those for the RTI and INI but with more complex four and five term denominators (not shown).</p>
      </sec>
      <sec id="s2c">
        <title>Model data</title>
        <p>The time delays between drug administration and effect on pVLs for the eight drugs from Murray <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref> are shown in <xref ref-type="table" rid="pcbi-1002971-t002">Table 2</xref>. It should be noted that for complexity reasons our model does not differentiate between different drugs that act on the same stage of the viral life cycle. Since we represent only one RTI in the model, the time delay determined for that stage was taken as the mean of the initial time delays of rilpivirine, abacavir, and tenofovir. We use the maraviroc time delay for EIs since its estimates were based on more patient data than for enfuvirtide. The PI delay is averaged from the fits to nelfinavir and ritonavir data. For the INI we use the delay for the only integrase inhibitor for which data are available, raltegravir.</p>
        <table-wrap id="pcbi-1002971-t002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002971.t002</object-id>
          <label>Table 2</label>
          <caption>
            <title>Monotherapy data.</title>
          </caption>
          <alternatives>
            <graphic id="pcbi-1002971-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002971.t002" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Individuals</td>
                  <td align="left" rowspan="1" colspan="1">Delay (hours)</td>
                  <td align="left" rowspan="1" colspan="1">Slope (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e100" xlink:type="simple"/></inline-formula>)</td>
                  <td align="left" rowspan="1" colspan="1">Std Dev. (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e101" xlink:type="simple"/></inline-formula>)</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">raltegravir</td>
                  <td align="left" rowspan="1" colspan="1">25</td>
                  <td align="left" rowspan="1" colspan="1">6.8</td>
                  <td align="left" rowspan="1" colspan="1">1.52</td>
                  <td align="left" rowspan="1" colspan="1">0.10</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">rilpivirine</td>
                  <td align="left" rowspan="1" colspan="1">36</td>
                  <td align="left" rowspan="1" colspan="1">11.4</td>
                  <td align="left" rowspan="1" colspan="1">0.93</td>
                  <td align="left" rowspan="1" colspan="1">0.42</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">abacavir</td>
                  <td align="left" rowspan="1" colspan="1">10</td>
                  <td align="left" rowspan="1" colspan="1">25.0</td>
                  <td align="left" rowspan="1" colspan="1">0.70</td>
                  <td align="left" rowspan="1" colspan="1">0.32</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">tenofovir</td>
                  <td align="left" rowspan="1" colspan="1">11</td>
                  <td align="left" rowspan="1" colspan="1">44.4</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">enfuvirtide</td>
                  <td align="left" rowspan="1" colspan="1">7</td>
                  <td align="left" rowspan="1" colspan="1">32.2</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">maraviroc</td>
                  <td align="left" rowspan="1" colspan="1">64</td>
                  <td align="left" rowspan="1" colspan="1">44.4</td>
                  <td align="left" rowspan="1" colspan="1">0.86</td>
                  <td align="left" rowspan="1" colspan="1">0.18</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">ritonavir</td>
                  <td align="left" rowspan="1" colspan="1">7</td>
                  <td align="left" rowspan="1" colspan="1">52.3</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">nelfinavir</td>
                  <td align="left" rowspan="1" colspan="1">5</td>
                  <td align="left" rowspan="1" colspan="1">51.6</td>
                  <td align="left" rowspan="1" colspan="1">1.50</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt102">
              <label/>
              <p>Initial delay and phase IA monotherapy slopes when fitting biphasic decay curves separately to each drug group <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>. Standard deviations (Std Dev.) were obtained from the nonlinear mixed effects calculations for each drug. The number of patients used in the analysis is also shown. The entries that are empty under the slope category did not admit nonlinear mixed effect fits due to insufficient data. The pharmacological delay has been subtracted from the delays.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Determining the initial delays was the main purpose of the Murray <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref> investigation. To accomplish this, nonlinear mixed effects modeling of the pVL dynamics were constrained to a first phase slope with the same fixed effect across all drug classes. However, further analysis of first phase slopes for individual drugs indicated these could differ depending on the stage of the viral life cycle being inhibited. The first phase slopes from the latter analysis are shown in <xref ref-type="table" rid="pcbi-1002971-t002">Table 2</xref>. Here we use the slopes of raltegravir, rilpivirine, and maraviroc for comparison with our model simulations using an INI, RTI, and EI respectively. No fitting of the phase IA slope for the PIs was employed given the small number of patients in the PI data. Although nonlinear mixed modeling indicated a decay rate of 1.5 <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e102" xlink:type="simple"/></inline-formula> for nelfinavir, data on which this analysis was performed after the 2 day initial delay for PIs were only available at days 3, 6, and 9 leading to considerable uncertainty in this estimate. The estimated slope for nelfinavir was inconsistent with the trend of all patient data.</p>
      </sec>
      <sec id="s2d">
        <title>Model optimization</title>
        <p>The longitudinal analysis of Murray <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>, clearly identified two parameters relevant for the phase I dynamics of drugs acting at different inhibition stages administered in monotherapy. These parameters, the initial time delay until viral load reduction and the phase IA decay slope, imply that two parameters can be used to constrain the model at each replication stage <xref ref-type="bibr" rid="pcbi.1002971-Herz1">[4]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Perelson2">[7]</xref>. This guided our construction of the stage dependant model as discussed previously. Since our model does not predict the time delays from first principles, we fix the observed time delays to those in <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref> (given in <xref ref-type="table" rid="pcbi-1002971-t002">Table 2</xref>).</p>
        <p>To fit the remaining phase IA slopes from the monotherapy data, we assume an efficacy of 90% for each drug (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e103" xlink:type="simple"/></inline-formula>), and optimize over five parameters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e104" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e105" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e106" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e107" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e108" xlink:type="simple"/></inline-formula>. These five parameters control the phase IA slopes, see <xref ref-type="disp-formula" rid="pcbi.1002971.e082">Eqs. 8</xref> and <xref ref-type="disp-formula" rid="pcbi.1002971.e091">9</xref>. As noted in Murray <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>, pVL decreased by more than 90% for each drug class indicating an efficacy of at least 90%. We note that we have five parameters and only three phase IA slopes meaning we can only formally constrain three parameters. However, given the model consists of a series of interconnected replication processes, the slope of later acting drugs (such as the EI) are not independent of the earlier replication processes (such as integration and viral production). This means we are able to obtain reasonable bounds on the parameters, except <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e109" xlink:type="simple"/></inline-formula> as discussed below. The remaining model parameters not listed above do not explicitly control the phase IA slopes of the various drug classes but influence phase IB. We fix these other parameters to those given in <xref ref-type="table" rid="pcbi-1002971-t001">Table 1</xref>. Note that the time delays in the model are corrected for the average half-life of progression in each stage <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e110" xlink:type="simple"/></inline-formula>. For the model optimization calculation we construct a chi-squared measure by comparing the modeled and observed phase IA slopes <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e111" xlink:type="simple"/></inline-formula>, where we sum over the drugs with reliable non-linear mixed effects phase IA slopes and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e112" xlink:type="simple"/></inline-formula> is the estimated standard deviation of the observed slopes (<xref ref-type="table" rid="pcbi-1002971-t002">Table 2</xref>). We combine the RTI errors via Monte Carlo to give <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e113" xlink:type="simple"/></inline-formula>. Only the phase IA slope of the viral decline is used to constrain the model, since it is largely independent of efficacy for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e114" xlink:type="simple"/></inline-formula>. Phase IB is sensitive to efficacy and other model parameters and is not used to constrain the model.</p>
        <p>To estimate the parameters that control the phase IA slope for the various drug classes, we use a five parameter optimization and grid search in 0.1 intervals from <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e115" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e116" xlink:type="simple"/></inline-formula> in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e117" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e118" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e119" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e120" xlink:type="simple"/></inline-formula>. For <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e121" xlink:type="simple"/></inline-formula> we use 0.05 intervals from <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e122" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e123" xlink:type="simple"/></inline-formula>. The optimal values for phase IA are given in <xref ref-type="table" rid="pcbi-1002971-t001">Table 1</xref>. To estimate the errors on the five parameters, the 95% confidence intervals are obtained by using a bootstrap method, randomly dropping 20% of data points for each drug and then re-running the optimization procedure. We also tested dropping 20% of patients with similar results. The error on each parameter was estimated with the other parameters held fixed at their optimal values. This gives at 95% confidence; <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e124" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e125" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e126" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e127" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e128" xlink:type="simple"/></inline-formula>. One parameter <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e129" xlink:type="simple"/></inline-formula> is only bounded below at 95% confidence due to there being only three non-linear mixed effects slopes. The best estimates for these parameters are provided in <xref ref-type="table" rid="pcbi-1002971-t001">Table 1</xref>.</p>
        <p>Matlab Version 2010b (The MathWorks Inc, Natick MA, USA) and Mathematica 8.0 (Wolfram Research, Champaign IL, USA) were used to solve the mathematical model and fit the monotherapy data.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <sec id="s3a">
        <title>Conditions leading to different decay slopes</title>
        <p>Our aim here is to show that by taking into account the stages inhibited by drugs, pVL can exhibit different first phase decay rates by drug class that are not simply determined by differing drug efficacy. As a consequence, even if the drugs have perfect efficacy (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e130" xlink:type="simple"/></inline-formula>) their slopes will differ. Under the assumption of perfect drug efficacy we can solve the system of differential equations <xref ref-type="disp-formula" rid="pcbi.1002971.e008">Eqs. 1</xref>–<xref ref-type="disp-formula" rid="pcbi.1002971.e014">7</xref> analytically which provides useful parameter bounds for the numerical computations. We presented the solutions for the INI and RTI in <xref ref-type="disp-formula" rid="pcbi.1002971.e082">Eqs. 8</xref> and <xref ref-type="disp-formula" rid="pcbi.1002971.e091">9</xref> respectively.</p>
        <p>Analysis of the perfect efficacy solutions for the INI and RTI viral load decays shows how the progression, death, and clearance rates can potentially determine the phase IA slope. For an INI with perfect efficacy <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e131" xlink:type="simple"/></inline-formula>, phase IA decay is determined by the rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e132" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e133" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e134" xlink:type="simple"/></inline-formula> (<xref ref-type="disp-formula" rid="pcbi.1002971.e082">Eq. 8</xref>). Since the viral clearance rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e135" xlink:type="simple"/></inline-formula> is much larger than any other progression or death rate parameter, it will not play a role in determining the phase IA slope. For the INI then, the phase IA slope will be given by the smallest of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e136" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e137" xlink:type="simple"/></inline-formula>. Similarly when perfect efficacy RTI monotherapy is applied <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e138" xlink:type="simple"/></inline-formula>, the phase IA slope is determined by the three rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e139" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e140" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e141" xlink:type="simple"/></inline-formula> (<xref ref-type="disp-formula" rid="pcbi.1002971.e091">Eq. 9</xref>).</p>
        <p>Comparison of the parameters controlling the phase IA decay show how the decay can be different between an INI and RTI. When the rates obey the inequalities <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e142" xlink:type="simple"/></inline-formula> or <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e143" xlink:type="simple"/></inline-formula>, the phase IA decay rate with an RTI is no different to that with an INI. However when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e144" xlink:type="simple"/></inline-formula> the phase IA decay rate for an INI will be larger than for an RTI. Hence phase IA decay slopes will differ for an RTI and an INI under the conditions that<disp-formula id="pcbi.1002971.e145"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002971.e145" xlink:type="simple"/><label>(10)</label></disp-formula>Note that if the death rate of cells in the early stages of infection <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e146" xlink:type="simple"/></inline-formula>, is equal to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e147" xlink:type="simple"/></inline-formula>, a phase IA slope difference will not be observed – implying <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e148" xlink:type="simple"/></inline-formula> if a large difference in INI and RTI decay slopes is observed. Similar bounds can be derived if decay rates differ with the other drug classes. We have illustrated these inequalities in <xref ref-type="fig" rid="pcbi-1002971-g002">Figure 2</xref>, which shows that when the variance of movement from RT complete to IN complete is large, i.e. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e149" xlink:type="simple"/></inline-formula> is small and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e150" xlink:type="simple"/></inline-formula> is true, the INI decay is steeper than the RTI, EI, and PI slope.</p>
        <fig id="pcbi-1002971-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002971.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Illustration of the different phase IA slope possibilities in the model.</title>
            <p>(A) When the productively infected death rate is low, or the rate to viral production is low, a difference in phase IA slopes is not seen between the drug classes. (B) When the progression rate to IN complete is low compared to the productively infected death rate or the rate to viral production, a phase IA slope difference will be observed. In this case the INI will have a steeper decay than the RTI, EI, or PI.</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002971.g002" position="float" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3b">
        <title>Comparison to observed monotherapy pVL decay</title>
        <p>To reproduce the measured phase IA decay rates for the four drug classes, the analysis above indicates the inequalities in <xref ref-type="disp-formula" rid="pcbi.1002971.e145">Eq. 10</xref> must hold and the death rate of productively infected CD4+ T cells <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e151" xlink:type="simple"/></inline-formula>, must be substantially larger than the death rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e152" xlink:type="simple"/></inline-formula> for cells that have not yet reached the stage of productive infection <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e153" xlink:type="simple"/></inline-formula> at perfect efficacy. Numerical solutions of the model with more realistic drug efficacies of 90%, and optimally chosen parameters, capture both the initial delays and the steeper phase IA decay slopes as the drug class acts closer to viral production (<xref ref-type="fig" rid="pcbi-1002971-g003">Figure 3</xref>). The distinct phase IA slopes in <xref ref-type="fig" rid="pcbi-1002971-g003">Figure 3</xref>, particularly for the INI, as well as the later phase IB profiles were all produced with the same 90% efficacy for each drug simulated as monotherapy. The optimal values for phase IA are given in <xref ref-type="table" rid="pcbi-1002971-t001">Table 1</xref>. Simulations for each of the uninfected and infected stages of CD4+ T cells, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e154" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e155" xlink:type="simple"/></inline-formula> are shown in <xref ref-type="fig" rid="pcbi-1002971-g004">Figure 4</xref>. We also overlay the pVL data and the model (<xref ref-type="fig" rid="pcbi-1002971-g005">Figure 5</xref>) with the parameters from <xref ref-type="table" rid="pcbi-1002971-t001">Table 1</xref>. Good agreement is seen across the drug classes with the optimally chosen model parameters.</p>
        <fig id="pcbi-1002971-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002971.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Phase IA and time delay comparison.</title>
            <p>Comparison of time delays and phase IA decay slopes from the data in <xref ref-type="table" rid="pcbi-1002971-t002">Table 2</xref> and the model with parameters given by <xref ref-type="table" rid="pcbi-1002971-t001">Table 1</xref>, with model simulations of monotherapy commencing at time <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e156" xlink:type="simple"/></inline-formula>. The y-axis shows virus levels normalized by baseline value at <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e157" xlink:type="simple"/></inline-formula>. The dotted, short dashed, long dashed, and solid lines are the model simulations in the presence of an INI, RTI, EI, or PI respectively. <italic>This convention is used in all subsequent figures</italic>. The indicated gray lines display the mean phase IA decay rates for the INI, RTI, and EI commencing after the initial delay for each drug (<xref ref-type="table" rid="pcbi-1002971-t002">Table 2</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>). No PI slope is shown due to insufficient data. Efficacy is set to 0.90 for each drug class.</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002971.g003" position="float" xlink:type="simple"/>
        </fig>
        <fig id="pcbi-1002971-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002971.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>Companion CD4+ T cell dynamics to <xref ref-type="fig" rid="pcbi-1002971-g003"><bold>Figure 3</bold></xref> for the optimal model.</title>
            <p>Here monotherapy is administered for the four different drug classes. All T cell species have been normalized to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e158" xlink:type="simple"/></inline-formula> and are denoted generically by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e159" xlink:type="simple"/></inline-formula>. (A) Productive CD4+ T cells. (B) CD4+ T cells with integration complete. (C) CD4+ T cells with reserve transcription complete. (D) CD4+ T cells with entry complete. (E) All CD4+ T cells irrespective of their infection stage, including uninfected CD4+ T cells. Comparison of (A) to <xref ref-type="fig" rid="pcbi-1002971-g003">Figure 3</xref> shows viral load tracks the number of CD4+ T cells producing virus <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e160" xlink:type="simple"/></inline-formula> regardless of drug class, with the remaining infected CD4+ T cell species dynamics depending on the stage of inhibition. The final panel (E) shows the sum of all CD4+ T cells in the model <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e161" xlink:type="simple"/></inline-formula>. Note that the target plus infected CD4+ T cells <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e162" xlink:type="simple"/></inline-formula> increase quasi-linearly as anticipated after the removal of the majority of infection with ART. Efficacy is 0.9.</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002971.g004" position="float" xlink:type="simple"/>
        </fig>
        <fig id="pcbi-1002971-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002971.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>Qualitative comparison with the raw plasma viral load data.</title>
            <p>The raw plasma viral load data from <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref> and the model with parameters given in <xref ref-type="table" rid="pcbi-1002971-t001">Table 1</xref> have been overlayed. The complete monotherapy data sets are shown. (A) For the INI, we show viral load data during raltegravir treatment. (B) For the RTI, rilpivirine, abacavir, and tenofovir are shown. (C) For the EI, enfuvirtide and maraviroc are shown. (D) For the PI, ritonavir and nelfinavir are shown. Good agreement is seen across the four drug classes in the model. We note the model is fitted to the longitudinal analysis of the assay data from <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>. Efficacy is set to 0.90 for each drug class.</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002971.g005" position="float" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3c">
        <title>The death rate of productively infected CD4+ T cells</title>
        <p>To reproduce the faster phase IA decay for the INI, we found the death rate of productively infected CD4+ T cells <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e163" xlink:type="simple"/></inline-formula>, must be substantially larger than the death rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e164" xlink:type="simple"/></inline-formula> for cells that have not yet reached the stage of productive infection <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e165" xlink:type="simple"/></inline-formula>. From our model, a productively infected death rate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e166" xlink:type="simple"/></inline-formula> allows us to model the steep phase IA decay of the INI, as shown in <xref ref-type="fig" rid="pcbi-1002971-g003">Figure 3</xref>. Based on our analysis we also found that the death rate for cells undergoing infection but which are not in the productive <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e167" xlink:type="simple"/></inline-formula> stage must be low with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e168" xlink:type="simple"/></inline-formula>, and smaller values of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e169" xlink:type="simple"/></inline-formula> than this bound produced better fits to the data. The upper bound of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e170" xlink:type="simple"/></inline-formula>, is considerably lower than the range of values for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e171" xlink:type="simple"/></inline-formula>. We also investigated the case where the death rate could differ by stage of infection rather than be fixed at the one value <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e172" xlink:type="simple"/></inline-formula>. However this did not produce substantially better fits and still required these death rates by stage to be less than <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e173" xlink:type="simple"/></inline-formula> as above.</p>
        <p>Simulations with the productively infected cell death rate set to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e174" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e175" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e176" xlink:type="simple"/></inline-formula> verify the influence that a high death rate in this stage can have on pVL dynamics (<xref ref-type="fig" rid="pcbi-1002971-g006">Figure 6A</xref>). We find that for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e177" xlink:type="simple"/></inline-formula>, which is still greater than the death rate estimated for productively infected CD4+ T cells in the literature of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e178" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1002971-Ho1">[1]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Perelson1">[3]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Perelson2">[7]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Markowitz1">[25]</xref> (where intracellular infection stages have not been included), the slope of phase IA does not appreciably differ between the drug classes, and does not duplicate the fast decay produced by the INI raltegravir. On the other hand, the larger values <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e179" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e180" xlink:type="simple"/></inline-formula> result in the fast decay achieved with an INI but also produce the slower rates of decay with other drug classes.</p>
        <fig id="pcbi-1002971-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002971.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>Comparison of pVL dynamics when individual model parameters are altered.</title>
            <p>Parameters are modified from those in <xref ref-type="table" rid="pcbi-1002971-t001">Table 1</xref>, while all other parameters are held constant. (A) From this panel we can see that the productively infected cell death rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e181" xlink:type="simple"/></inline-formula> can control the slope in phase IA and the relative difference between phase IA slopes. (B) As efficacy <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e182" xlink:type="simple"/></inline-formula> is changed, the phase IA slope is not strongly altered. However, the length of phase IA and the start of phase IB at <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e183" xlink:type="simple"/></inline-formula> are dependent on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e184" xlink:type="simple"/></inline-formula>. (C) Modifying the viral clearance rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e185" xlink:type="simple"/></inline-formula> changes the initial delay slightly, but does not substantially modify phase IA. After the transition to phase IB, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e186" xlink:type="simple"/></inline-formula> influences the decay considerably. (D) The production rate of uninfected CD4+ T cells <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e187" xlink:type="simple"/></inline-formula>, and (E) virion production rate per productively infected CD4+ T cell <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e188" xlink:type="simple"/></inline-formula>. Both <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e189" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e190" xlink:type="simple"/></inline-formula> do not modify the time delays or phase IA, but affect phase IB. Efficacy is set to 0.90 in (A) and (C)–(E).</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002971.g006" position="float" xlink:type="simple"/>
        </fig>
        <p>This behavior with large values for the productively infected death rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e191" xlink:type="simple"/></inline-formula> is predicted by the analytically-derived solution under the assumption of complete efficacy for the individual drugs. As discussed for the exact solution, we find that as the productively infected death rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e192" xlink:type="simple"/></inline-formula> increases above the sum of the death and the progression rate of the previous infection stages, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e193" xlink:type="simple"/></inline-formula>, then the phase IA slopes become significantly steeper for the INI compared to an RTI and the other drug classes. The optimal parameter values for the model assuming non-perfect efficacy of 90% of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e194" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e195" xlink:type="simple"/></inline-formula>, are consistent with this relationship.</p>
      </sec>
      <sec id="s3d">
        <title>Variability around the average time delay</title>
        <p>Although the mean time delay between stages of infection is mostly determined by the values <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e196" xlink:type="simple"/></inline-formula>, the progression rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e197" xlink:type="simple"/></inline-formula> impact on the variability around this mean; high progression rates lead to all cells progressing from one stage to the next at almost the same time <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e198" xlink:type="simple"/></inline-formula>; low progression rates lead to some cells progressing slowly and others quickly, a much more heterogeneous process. The sharpness of the transition after the time delay to phase IA is controlled by the progression rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e199" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e200" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e201" xlink:type="simple"/></inline-formula> in a similar manner. For example in <xref ref-type="fig" rid="pcbi-1002971-g003">Figure 3</xref>, we see the transition is particularly sharp for the INI, whereas for the PI, a more extensive shoulder is observed. Since the effect is cumulative with respect to the progression rates, the INI produces a sharp transition since it only depends on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e202" xlink:type="simple"/></inline-formula>, whereas the EI and PI transition to the phase IA decay will depend on the size of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e203" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e204" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e205" xlink:type="simple"/></inline-formula>.</p>
        <p>Slow progression rates for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e206" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002971-g007">Figure 7A</xref>) and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e207" xlink:type="simple"/></inline-formula> (not shown), or large variability about the mean time, lead to large phase IA slope differences between drug classes acting on either side of the respective stage in the life cycle. Our exact solution to the model with complete efficacy also predicted this behavior. This is observed in the monotherapy data of <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref> which indicated <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e208" xlink:type="simple"/></inline-formula> is small, rather than <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e209" xlink:type="simple"/></inline-formula>. For completeness we also plot in <xref ref-type="fig" rid="pcbi-1002971-g007">Figure 7B</xref> <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e210" xlink:type="simple"/></inline-formula> relative to baseline, showing the long slow decline of the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e211" xlink:type="simple"/></inline-formula> curve resulting from small values <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e212" xlink:type="simple"/></inline-formula>. As our RT stage was set at the average time for when reverse transcription occurs over a 33 hour time period, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e213" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e214" xlink:type="simple"/></inline-formula> describe the rates leading up to and progressing from this mid-point, the low values of these rates are consistent with the slow completion of RT and/or IN.</p>
        <fig id="pcbi-1002971-g007" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002971.g007</object-id>
          <label>Figure 7</label>
          <caption>
            <title>Influence of the progression rate to IN, </title>
            <p><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e215" xlink:type="simple"/></inline-formula><bold>, on the pVL curves.</bold> (A) A relatively low rate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e216" xlink:type="simple"/></inline-formula> (black curves) giving a variance of 0.5 days around the mean time to IN <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e217" xlink:type="simple"/></inline-formula>, leads to a large slope difference between the INI and RTI, compared to a fast rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e218" xlink:type="simple"/></inline-formula> (gray curves) with standard deviation of 0.1 days around the mean for virus progressing from the middle of RT to IN. (B) In this panel, we show how the CD4+ T cells move from RT to IN for all drug classes. For <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e219" xlink:type="simple"/></inline-formula>, note the relatively slow rate at which the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e220" xlink:type="simple"/></inline-formula> progress from the RT stage and move to IN, is reflected in the slow decrease in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e221" xlink:type="simple"/></inline-formula>. An efficacy of 0.95 is used for each drug.</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002971.g007" position="float" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3e">
        <title>Drug class efficacy and the first phase</title>
        <p>Although drug efficacy will modify the phase IA slope at low levels, once above a certain efficacy of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e222" xlink:type="simple"/></inline-formula>, the phase IA slope is determined by other effects, such as the decay rate of productively infected CD4+ T cells as described above. Sensitivity of phase IA and IB decay to different efficacy rates are shown in <xref ref-type="fig" rid="pcbi-1002971-g006">Figure 6B</xref>. At higher efficacy, we observe a lengthening of the phase IA decay, but no change in the decay rate, and the damping of any other effects due to the time delays in the decay curves.</p>
        <p>Drug efficacy can significantly modify phase IB, the slower part of the traditional first phase decay, as observed by Murray <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref> and has also been commented on by other investigators <xref ref-type="bibr" rid="pcbi.1002971-Markowitz1">[25]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Grossman1">[29]</xref>. The phase IB decay rates depend on all model parameters but the relative pVL at which this phase occurs is dependent on drug efficacy, as well as drug class. The pVL relative to baseline is approximately <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e223" xlink:type="simple"/></inline-formula> so that greater efficacy results in a more substantial decrease before the commencement of phase IB (<xref ref-type="fig" rid="pcbi-1002971-g006">Figure 6B</xref>). These results indicate that phase IB originates from new rounds of infection that progress despite the presence of the drug.</p>
      </sec>
      <sec id="s3f">
        <title>Virion clearance rate</title>
        <p>The virion clearance rate in the model was fixed at <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e224" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1002971-Ramratnam1">[9]</xref>. To determine if <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e225" xlink:type="simple"/></inline-formula> had any appreciable effect on the phase IA dynamics, we examined different values of the clearance rate, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e226" xlink:type="simple"/></inline-formula> as determined by <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>, and a smaller value <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e227" xlink:type="simple"/></inline-formula>. As seen in <xref ref-type="fig" rid="pcbi-1002971-g006">Figure 6C</xref>, the value of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e228" xlink:type="simple"/></inline-formula> has little effect on the total time delay associated with each drug class and produces no appreciable modification of phase IA. The virion clearance rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e229" xlink:type="simple"/></inline-formula> controls the length of time circulating virus is available to infect CD4+ T cells through the infection term <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e230" xlink:type="simple"/></inline-formula>. This means that changes in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e231" xlink:type="simple"/></inline-formula> will modify phase IB in the pVL curves (<xref ref-type="fig" rid="pcbi-1002971-g006">Figure 6C</xref>).</p>
      </sec>
      <sec id="s3g">
        <title>Target cell production</title>
        <p>The availability of target cells was determined by the parameter <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e232" xlink:type="simple"/></inline-formula>. Its value had no effect on the delay or phase IA slope (<xref ref-type="fig" rid="pcbi-1002971-g006">Figure 6D</xref>). However, as the production rate of target cells <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e233" xlink:type="simple"/></inline-formula> is increased, there was a more prominent slowing of the phase IB decay at later times. This indicates that the availability of target cells to infection plays an important role in phase IB, and further implies that phase IB results from new rounds of infection by circulating virions. We note that increasing the number <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e234" xlink:type="simple"/></inline-formula> of virions produced has a similar effect to increasing <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e235" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002971-g006">Figure 6E</xref>).</p>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>With the increasing number of antiretroviral drug classes, monotherapy and other trials provide data that allows examination of the HIV life cycle in greater detail than ever before. A recent study of monotherapy trials by Murray <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>, demonstrated a systematic trend in the observed time delays of pVL curves – as the drug class acts further from viral export, the initial delay increases. To examine the effect of the HIV replication cycle on pVL curves and first phase dynamics, we created a mathematical model explicitly incorporating stages of the life cycle of HIV in CD4+ T cells.</p>
      <p>We found that with stage-dependent drug action, the traditional first phase which arises from productively infected CD4+ T cells, has three components: 1) an initial delay preceding any decrease in the pVL curves after commencing monotherapy, 2) a steep decay at the end of this shoulder, which we call phase IA, and 3) a slower decay, called phase IB, that starts at day 2–4. The precise characteristics of these three features depends on where the drug intervenes in the viral life cycle, and on the mean and variance of the time required to progress between different stages of infection (determined by parameters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e236" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e237" xlink:type="simple"/></inline-formula>). The observed initial delay describes the time from a given stage in the viral life cycle until virion export. The slope of phase IA is determined by the drug class/classes being used, the death rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e238" xlink:type="simple"/></inline-formula> of productively infected cells and the progression rates between viral life cycle stages: <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e239" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e240" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e241" xlink:type="simple"/></inline-formula>. The length of phase IA is largely determined by drug efficacy but is also influenced by the drug class/classes being used (<xref ref-type="fig" rid="pcbi-1002971-g006">Figure 6B</xref>). Phase IB is sensitive to most parameters in the model, since it is a result of new rounds of infection. Plasma virus levels are substantially lower at initiation of phase IB at larger drug efficacy and phase IB pVLs remain higher with greater target cell availability. <xref ref-type="fig" rid="pcbi-1002971-g008">Figure 8</xref> summarizes the main features observed from the data and duplicated by our model.</p>
      <fig id="pcbi-1002971-g008" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1002971.g008</object-id>
        <label>Figure 8</label>
        <caption>
          <title>Plasma HIV RNA curves for the four drug classes INI, RTI, EI, and PI.</title>
          <p>The dotted, short dashed, long dashed, and solid lines are model simulations where the effects of an INI, RTI, EI, and PI respectively were modeled. The key features of the model have been labeled. The time delays are given by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e242" xlink:type="simple"/></inline-formula>. An efficacy of 0.95 has been used for each drug.</p>
        </caption>
        <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002971.g008" position="float" xlink:type="simple"/>
      </fig>
      <p>One of the main motivations for investigating a stage-dependent model of HIV decay kinetics was to understand the observed differences in phase IA slopes between INIs and RTIs, EIs, and PIs. Specifically, what mechanisms lead to INIs having steeper phase IA pVL decays? Nelson <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1002971-Nelson3">[15]</xref> showed a time delay can change the slope of phase IA by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e243" xlink:type="simple"/></inline-formula> 20% depending on the efficacy; however, this cannot account for the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e244" xlink:type="simple"/></inline-formula> faster decay for raltegravir compared to rilpivirine (<xref ref-type="table" rid="pcbi-1002971-t002">Table 2</xref>). In our analysis we determined a large slope difference is achievable, but only under certain conditions. These are: (1) there is a substantial variance around the mean in the commencement times for the stage that includes part of RT plus IN of HIV DNA, with the progression rate being on the order of the mean time <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e245" xlink:type="simple"/></inline-formula>, (2) the death rate of productively infected CD4+ T cells must be high at a rate of approximately <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e246" xlink:type="simple"/></inline-formula>, (3) after HIV DNA integration all cells that are to become productively infected without an intervening latent stage will do so quickly with a small variance (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e247" xlink:type="simple"/></inline-formula>), (4) the viral clearance rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e248" xlink:type="simple"/></inline-formula> is also high, and (5) the death rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e249" xlink:type="simple"/></inline-formula> of the infected but unproductive stages are low and specifically must satisfy <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e250" xlink:type="simple"/></inline-formula>. Under our mathematical modeling, all of these conditions must hold for a large difference in slopes to be observed as described in Murray <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>. Given these conditions are independent of specific antiretroviral effects, they inform the biology of the interaction between HIV-1, CD4+ T cells, and the immune system.</p>
      <p>A large death rate of productively infected cells <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e251" xlink:type="simple"/></inline-formula> (half life of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e256" xlink:type="simple"/></inline-formula> 8 hours), was required to model the monotherapy pVL decay data. Previous values in the literature estimated a productively infected CD4+ T cell death rate of approximately <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e252" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1002971-Ho1">[1]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Perelson1">[3]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Perelson2">[7]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Markowitz1">[25]</xref>. These estimates mostly did not include a directly calculated initial delay, nor did they discriminate between the two parts of the first phase, phase IA and IB, that have now been observed by a number of investigators <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Markowitz1">[25]</xref>, <xref ref-type="bibr" rid="pcbi.1002971-Grossman1">[29]</xref>. Furthermore no consideration was given to the drug class/classes being used, which we have seen to considerably influence the rate of decay over the first 10 days of ART (<xref ref-type="fig" rid="pcbi-1002971-g003">Figure 3</xref>).</p>
      <p>Our models shows that the slope of phase IA is not simply determined by the death rate of productively infected cells <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e253" xlink:type="simple"/></inline-formula>, but is also determined by the rate at which cells progress through the stages of infection. For example, for an INI we must also account for the rate at which integrated CD4+ T cells become productively infected at the rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e254" xlink:type="simple"/></inline-formula>. The phase IA slope is then approximately given by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e255" xlink:type="simple"/></inline-formula>, consistent with the observed phase IA INI slope (<xref ref-type="table" rid="pcbi-1002971-t002">Table 2</xref>). This means movement through the entire replication cycle must be considered when estimating phase IA slopes.</p>
      <p>We determined the productively infected stage of an infected cell has a half-life of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e256" xlink:type="simple"/></inline-formula> 8 hours with average duration of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e257" xlink:type="simple"/></inline-formula> 12 hours. In <xref ref-type="bibr" rid="pcbi.1002971-Murray2">[6]</xref> the total HIV life cycle was determined to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e258" xlink:type="simple"/></inline-formula> hours. This implies there are approximately 3-fold more cells in the early stages of infection than actually producing virions, and suggests that viral proteins such as <italic>tat</italic> produced soon after integration, are produced relatively late in the total viral infection cycle. Of the infected cells that are not yet productive, about 2/3 are in the RT stage.</p>
      <p>Both the numerical and analytical solutions indicated that the death rate of cells in the early stages of infection <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e259" xlink:type="simple"/></inline-formula> (95% confidence interval of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e260" xlink:type="simple"/></inline-formula>), is much lower than the death rate during the productively infected stage <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e261" xlink:type="simple"/></inline-formula>. The value <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002971.e262" xlink:type="simple"/></inline-formula> corresponds to an average lifespan of 20 days for these cells and is hence not much different to the lifespan of uninfected target cells which are most likely in an activated state. <italic>In vitro</italic> analysis has indicated that CD8+ T cells can recognize gag-derived epitopes within the first 2 hours of SIV infection of primary CD4+ T cell lines and are capable of eliminating these cells early in the infection cycle <xref ref-type="bibr" rid="pcbi.1002971-Sacha1">[30]</xref>. Our <italic>in vivo</italic> analysis on the other hand, indicates early immune recognition of CD4+ T cellular infection is compromised, possibly due to loss of HIV-specific CD4+ T cell help at primary infection <xref ref-type="bibr" rid="pcbi.1002971-Oxenius1">[31]</xref>, or that immune clearance is abrogated by persistent viremia <xref ref-type="bibr" rid="pcbi.1002971-Younes1">[32]</xref>. This suggests that <italic>in vivo</italic> expression of cytotoxic T cell epitopes by infected CD4+ T cells only occurs efficiently once viral proteins are made <italic>de novo</italic> from the integrated provirus. This is consistent with the current understanding of the processing and presentation of antigens through the MHC-class I pathway <xref ref-type="bibr" rid="pcbi.1002971-Apcher1">[33]</xref>. This delay may be critical for viral control and may explain the delays that compromise the effectiveness of CD8+ T cell cytotoxic responses in controlling the virus infection <xref ref-type="bibr" rid="pcbi.1002971-Davenport1">[34]</xref>. Further this delay may be exacerbated by Nef-induced down-regulation of MHC-I and CD4, which tends to make these cells more immunological silent to cytotoxic T cells and therefore more difficult to clear <xref ref-type="bibr" rid="pcbi.1002971-Agopian1">[35]</xref>. This delay in immune clearance of infected cells may be due to viral processes blocking pathways leading to apoptosis. The expression of Nef proteins early in the infection cycle and intercellular contact with macrophages has been observed to reduce apoptosis of cells proceeding to infection <xref ref-type="bibr" rid="pcbi.1002971-Mahlknecht1">[36]</xref>. Our modeling cannot determine the processes behind the large clearance rate at the productively infected stage so that either cytopathic effects of virus production or immune-mediated destruction may be responsible.</p>
      <p>Further, our analysis also reveals that relative drug efficacy may be measured very early, through the length of phase IA. This may prove useful in the early stages of drug development. Our mathematical model incorporating the stages of HIV infection has proved instrumental in explaining a number of as yet unexplained features from pVL curves under different antiretroviral drug classes.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="pcbi.1002971-Ho1">
        <label>1</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ho</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Leonard</surname><given-names>JM</given-names></name>, <etal>et al</etal>. (<year>1995</year>) <article-title>Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection</article-title>. <source>Nature</source> <volume>373</volume>: <fpage>123</fpage>–<lpage>126</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Wei1">
        <label>2</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>VA</given-names></name>, <name name-style="western"><surname>Emini</surname><given-names>EA</given-names></name>, <etal>et al</etal>. (<year>1995</year>) <article-title>Viral dynamics in human immunodeficiency virus type 1 infection</article-title>. <source>Nature</source> <volume>373</volume>: <fpage>117</fpage>–<lpage>122</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Perelson1">
        <label>3</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name>, <name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Leonard</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>DD</given-names></name> (<year>1996</year>) <article-title>HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time</article-title>. <source>Science</source> <volume>271</volume>: <fpage>1582</fpage>–<lpage>1586</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Herz1">
        <label>4</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Herz</surname><given-names>AVM</given-names></name>, <name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>May</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Nowak</surname><given-names>MA</given-names></name> (<year>1996</year>) <article-title>Viral dynamics <italic>in vivo</italic>: Limitations on estimates of intracellular delay and virus decay</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>93</volume>: <fpage>7247</fpage>–<lpage>7251</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Murray1">
        <label>5</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Murray</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Emery</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kelleher</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Law</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase</article-title>. <source>AIDS</source> <volume>21</volume>: <fpage>2315</fpage>–<lpage>2321</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Murray2">
        <label>6</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Murray</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Kelleher</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>DA</given-names></name> (<year>2011</year>) <article-title>Timing of the components of the HIV life cycle in productively infected CD4+ T cells in populations of HIV infected individuals</article-title>. <source>J Virol</source> <volume>85</volume>: <fpage>10798</fpage>–<lpage>10805</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Perelson2">
        <label>7</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Essunger</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Vesanen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hurley</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>1997</year>) <article-title>Decay characteristics of HIV-1-infected compartments during combination therapy</article-title>. <source>Nature</source> <volume>387</volume>: <fpage>188</fpage>–<lpage>191</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Bonhoeffer1">
        <label>8</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>May</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Shaw</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Nowak</surname><given-names>MA</given-names></name> (<year>1997</year>) <article-title>Virus dynamics and drug therapy</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>94</volume>: <fpage>6971</fpage>–<lpage>6976</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Ramratnam1">
        <label>9</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ramratnam</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Binley</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hurley</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis</article-title>. <source>Lancet</source> <volume>354</volume>: <fpage>1782</fpage>–<lpage>1785</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Lloyd1">
        <label>10</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lloyd</surname><given-names>AL</given-names></name> (<year>2001</year>) <article-title>The dependence of viral parameter estimates on the assumed viral life cycle: limitations of studies of viral load data</article-title>. <source>Proc Biol Sci</source> <volume>268</volume>: <fpage>847</fpage>–<lpage>854</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Mittler1">
        <label>11</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mittler</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Sulzer</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>1998</year>) <article-title>Influence of delayed viral production on viral dynamics in HIV-1 infected patients</article-title>. <source>Math Biosci</source> <volume>152</volume>: <fpage>143</fpage>–<lpage>163</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Dixit1">
        <label>12</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dixit</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2004</year>) <article-title>Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy</article-title>. <source>Antiviral Therapy</source> <volume>9</volume>: <fpage>237</fpage>–<lpage>246</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Nelson1">
        <label>13</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nelson</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Murray</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2000</year>) <article-title>A model of HIV-1 pathogenesis that includes an intracellular delay</article-title>. <source>Math Biosci</source> <volume>163</volume>: <fpage>201</fpage>–<lpage>215</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Nelson2">
        <label>14</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nelson</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Mittler</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2001</year>) <article-title>Effect of Drug Efficacy and the Eclipse Phase of the Viral Life Cycle on Estimates of HIV Viral Dynamics Parameters</article-title>. <source>AIDS</source> <volume>26</volume>: <fpage>405</fpage>–<lpage>412</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Nelson3">
        <label>15</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nelson</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2002</year>) <article-title>Mathematical analysis of delay differential equation models of HIV-1 infection</article-title>. <source>Math Biosci</source> <volume>179</volume>: <fpage>73</fpage>–<lpage>94</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Dixit2">
        <label>16</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dixit</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2004</year>) <article-title>Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay</article-title>. <source>J Theor Biol</source> <volume>226</volume>: <fpage>95</fpage>–<lpage>109</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Ouifki1">
        <label>17</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ouifki</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Witten</surname><given-names>G</given-names></name> (<year>2009</year>) <article-title>Stability analysis of a model for HIV infection with RTI and three intracellular delays</article-title>. <source>BioSystems</source> <volume>95</volume>: <fpage>1</fpage>–<lpage>6</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Sedaghat1">
        <label>18</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sedaghat</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Dinoso</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wilke</surname><given-names>CO</given-names></name>, <name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name> (<year>2008</year>) <article-title>Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>105</volume>: <fpage>4832</fpage>–<lpage>4837</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-vonKleist1">
        <label>19</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>von Kleist</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Menz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Huisinga</surname><given-names>W</given-names></name> (<year>2010</year>) <article-title>Drug-class specific impact of antivirals on the reproductive capacity of HIV</article-title>. <source>PLoS Comput Biol 26</source> <volume>6</volume> (<issue>3</issue>)  <fpage>e1000720</fpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Donahue1">
        <label>20</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Donahue</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Sloan</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Kuhl</surname><given-names>BD</given-names></name>, <name name-style="western"><surname>Bar-Magen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Schader</surname><given-names>SM</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Stage-Dependent Inhibition of HIV-1 Replication by Antiretroviral Drugs in Cell Culture</article-title>. <source>Antimicrob Agents Chemother</source> <volume>54</volume>: <fpage>1047</fpage>–<lpage>1054</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Goebel1">
        <label>21</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goebel</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Yakovlev</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pozniak</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Vinogradova</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Boogaerts</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Short-term antiviral activity of TMC278–a novel NNRTI–in treatment-naive HIV-1-infected subjects</article-title>. <source>AIDS</source> <volume>20</volume>: <fpage>1721</fpage>–<lpage>1726</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Goicoechea1">
        <label>22</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goicoechea</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jain</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kemper</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Daar</surname><given-names>ES</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients</article-title>. <source>AIDS</source> <volume>24</volume>: <fpage>707</fpage>–<lpage>716</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Kilby1">
        <label>23</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kilby</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Hopkins</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Venetta</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>DiMassimo</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Cloud</surname><given-names>GA</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry</article-title>. <source>Nat Med</source> <volume>4</volume>: <fpage>1302</fpage>–<lpage>1307</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Fatkenheuer1">
        <label>24</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fatkenheuer</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pozniak</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Plettenberg</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Staszewski</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1</article-title>. <source>Nat Med</source> <volume>11</volume>: <fpage>1170</fpage>–<lpage>1172</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Markowitz1">
        <label>25</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Louie</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hurley</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Di Mascio</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo</article-title>. <source>J Virol</source> <volume>77</volume>: <fpage>5037</fpage>–<lpage>5038</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Moyle1">
        <label>26</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moyle</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Youle</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Higgs</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Monaghan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Prince</surname><given-names>W</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus</article-title>. <source>J Clin Pharmacol</source> <volume>38</volume>: <fpage>736</fpage>–<lpage>743</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Kim1">
        <label>27</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Byrn</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Groopman</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Baltimore</surname><given-names>D</given-names></name> (<year>1989</year>) <article-title>Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression</article-title>. <source>J Virol</source> <volume>63</volume>: <fpage>3708</fpage>–<lpage>3713</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Doitsh1">
        <label>28</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Doitsh</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Cavrois</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lassen</surname><given-names>KG</given-names></name>, <name name-style="western"><surname>Zepeda</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Abortive HIV Infection Mediates CD4 T Cell Depletion and Inflammation in Human Lymphoid Tissue</article-title>. <source>Cell</source> <volume>143</volume>: <fpage>789</fpage>–<lpage>801</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Grossman1">
        <label>29</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grossman</surname><given-names>ZM</given-names></name>, <name name-style="western"><surname>Polis</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Feinberg</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Levi</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Jankelevich</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Ongoing HIV dissemination during HAART</article-title>. <source>Nat Med</source> <volume>5</volume>: <fpage>1099</fpage>–<lpage>1104</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Sacha1">
        <label>30</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sacha</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Rakasz</surname><given-names>EG</given-names></name>, <name name-style="western"><surname>Spencer</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Jonas</surname><given-names>AK</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and protein expression</article-title>. <source>J Immunol</source> <volume>178</volume>: <fpage>2746</fpage>–<lpage>2754</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Oxenius1">
        <label>31</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Oxenius</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Easterbrook</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>O'Callaghan</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Kelleher</surname><given-names>AD</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>97</volume>: <fpage>3382</fpage>–<lpage>3387</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Younes1">
        <label>32</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Younes</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Yassine-Diab</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Dumont</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Boulassel</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Grossman</surname><given-names>Z</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>HIV-1 Viremia Prevents the Establishment of Interleukin 2producing HIV-specific Memory CD4+ T Cells Endowed with Proliferative Capacity</article-title>. <source>JEM</source> <volume>198</volume>: <fpage>1909</fpage>–<lpage>1922</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Apcher1">
        <label>33</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Apcher</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Manoury</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Fåhraeus</surname><given-names>R</given-names></name> (<year>2012</year>) <article-title>The role of mRNA translation in direct MHC class I antigen presentation</article-title>. <source>Curr Opin Immunol</source> <volume>24</volume>: <fpage>71</fpage>–<lpage>76</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Davenport1">
        <label>34</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Davenport</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2007</year>) <article-title>Understanding the mechanisms and limitations of immune control of HIV</article-title>. <source>Immunol Rev</source> <volume>216</volume>: <fpage>164</fpage>–<lpage>175</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Agopian1">
        <label>35</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Agopian</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Garcia</surname><given-names>JV</given-names></name>, <name name-style="western"><surname>Gabuzda</surname><given-names>D</given-names></name> (<year>2007</year>) <article-title>CD4 and MHC-I downregulation are conserved in primary HIV-1 Nef alleles from brain and lymphoid tissues, but Pak2 activation is highly variable</article-title>. <source>Virology</source> <volume>358</volume>: <fpage>119</fpage>–<lpage>135</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002971-Mahlknecht1">
        <label>36</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mahlknecht</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Greenough</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Sullivan</surname><given-names>JL</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Resistance to Apoptosis in HIV-Infected CD4+ T Lymphocytes Is Mediated by Macrophages: Role for Nef and Immune Activation in Viral Persistence</article-title>. <source>J Immunol</source> <volume>165</volume>: <fpage>6437</fpage>–<lpage>6446</lpage>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>